Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges.

Autor: Warner BM; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Yates JGE; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada., Vendramelli R; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Truong T; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Meilleur C; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Chan L; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada., Leacy A; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada., Pham PH; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada., Pei Y; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada., Susta L; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada. lsusta@uoguelph.ca., Wootton SK; Department of Pathobiology, University of Guelph, Guelph, N1G 2W1, Canada. kwootton@uoguelph.ca., Kobasa D; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada. darwyn.kobasa@phac-aspc.gc.ca.; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada. darwyn.kobasa@phac-aspc.gc.ca.
Jazyk: angličtina
Zdroj: NPJ vaccines [NPJ Vaccines] 2024 May 23; Vol. 9 (1), pp. 90. Date of Electronic Publication: 2024 May 23.
DOI: 10.1038/s41541-024-00870-8
Abstrakt: The rapid development and deployment of vaccines following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been estimated to have saved millions of lives. Despite their immense success, there remains a need for next-generation vaccination approaches for SARS-CoV-2 and future emerging coronaviruses and other respiratory viruses. Here we utilized a Newcastle Disease virus (NDV) vectored vaccine expressing the ancestral SARS-CoV-2 spike protein in a pre-fusion stabilized chimeric conformation (NDV-PFS). When delivered intranasally, NDV-PFS protected both Syrian hamsters and K18 mice against Delta and Omicron SARS-CoV-2 variants of concern. Additionally, intranasal vaccination induced robust, durable protection that was extended to 6 months post-vaccination. Overall, our data provide evidence that NDV-vectored vaccines represent a viable next-generation mucosal vaccination approach.
(© 2024. Crown.)
Databáze: MEDLINE
Externí odkaz: